Targeted disruption of the MHC cell receptor
AssigneeSangamo Therapeutics, Inc.
InventorsGary K. Lee, David Paschon, Lei Zhang
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods and compositions for inactivating MHC genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided.
Claims8
An isolated cell in which expression of a beta 2microglobulin (B2M) gene is partially or fully inactivated by an insertion and/or deletion within GGCCTTA, TCAAAT, TCAAATT, TTACTGA and/or AATTGAA of exon 1 or exon 2 of the B2M gene.
Dependencies are inferred from the claim text.